Welcome to our dedicated page for Inventiva S.A. SEC filings (Ticker: IVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inventiva S.A. American Depositary Shares (IVA) SEC filings page brings together the company’s regulatory disclosures as a foreign private issuer. Inventiva reports under the Exchange Act on Form 20-F and furnishes current information on Form 6-K, making these filings a primary source of insight into its biopharmaceutical research activities and corporate actions.
Recent Form 6-K filings referenced for Inventiva include press releases, interim financial reports, notices and documentation for Ordinary and Extraordinary General Meetings, proxy cards and voting instructions for holders of American Depositary Shares. One Form 6-K dated November 13, 2025 describes an underwriting agreement with Leerink Partners LLC and Piper Sandler & Co. for a public offering of ADSs under a shelf registration statement on Form F-3, illustrating how the company uses SEC-registered offerings to raise capital.
On this page, users can access Inventiva’s filings as they are made available through EDGAR, including annual reports on Form 20-F and current reports on Form 6-K. These documents may cover topics such as interim financial information, shareholder meeting procedures, and legal opinions related to securities offerings. For a biopharmaceutical company focused on drug candidates acting on nuclear receptors, transcription factors and epigenetic modulation, these filings help clarify how research programs and partnerships are reflected in its regulatory reporting.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in plain language, helping readers interpret complex documents such as registration statements on Form F-3 or detailed exhibits attached to Form 6-K. Real-time updates from EDGAR, combined with simplified explanations, allow investors to review Inventiva’s regulatory history, capital-raising transactions and governance disclosures in a more accessible format.
Inventiva S.A. filed a Form 6-K as a foreign private issuer to provide investors with two key documents for the first half of 2025. The company furnished its Interim Financial Report for the six months ended June 30, 2025 as Exhibit 99.1 and a press release dated September 29, 2025 reporting unaudited first-half 2025 financial results and a corporate update as Exhibit 99.2. The filing is an information update and does not itself describe specific financial figures or major transactions.
Inventiva S.A. Schedule 13G/A reports that BioDiscovery 6 FPCI is the record holder of 12,296,295 ordinary shares, representing 8.8% of the company’s ordinary share class based on 139,151,274 shares outstanding as of May 7, 2025. Voting and dispositive authority for those shares is exercised by Andera Partners as BioDiscovery 6’s management company, and the managing partners Stephane Bergez and Francois Xavier Mauron are identified as having shared voting and dispositive power. Each Reporting Person reports 0 sole voting or dispositive power and 12,296,295 shared voting and dispositive power as of June 30, 2025.
Invus Public Equities, L.P. and its controlled affiliates (Invus Public Equities Advisors LLC, Invus Global Management LLC, Siren LLC) together with managing member Raymond Debbane filed Amendment No. 1 to Schedule 13G on 31 Jul 2025, disclosing ownership of 14,814,813 ordinary shares of Inventiva S.A. (IVA) as of 30 Jun 2025.
The position represents 10.6 % of Inventiva’s 139,151,274 shares outstanding (per the issuer’s 6-K dated 5 May 2025). Each reporting person holds sole voting and dispositive power over the entire block; no shared power is reported and the filing certifies the stake is passive under Rule 13d-1(c).
The shares referenced are the issuer’s ordinary shares (EUR 0.01 nominal value). CUSIP 46124U107 applies to Inventiva’s American Depositary Shares, traded on Nasdaq (1 ADS = 1 ordinary share). No derivatives, options or other classes are disclosed. The filing contains no indication of intent to influence control and no group status beyond the affiliated Invus entities.
Key takeaway: Invus, a long-term healthcare investor, now owns a low-double-digit passive stake, giving it meaningful economic exposure without triggering control provisions.
Schedule 13G filing: Great Point Partners, LLC ("Great Point"), along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, report a new 7.42 % passive stake in Inventiva S.A. (CUSIP F5R343107) as of 05 May 2025.
The group beneficially owns 10,576,827 ordinary shares, comprised of 7,243,495 shares held outright and warrants for 3,333,332 shares. The ownership calculation is based on 139,151,274 shares outstanding plus the warrant shares, as disclosed in Inventiva’s 6-K dated 05 May 2025.
- Great Point Partners, LLC is an investment adviser organised in Delaware and files as an IA/OO.
- Dr. Jay (Senior Managing Member) and Ms. Nordahl (Managing Director) each file as HC/IN with shared voting and dispositive power over the entire position; neither has sole power.
- The shares are held through two health-care–focused funds: Biomedical Value Fund, L.P. (4,853,356 shares + 2,166,666 warrants) and Biomedical Offshore Value Fund, Ltd. (2,390,139 shares + 1,166,666 warrants).
- The reporting persons expressly disclaim beneficial ownership except to the extent of their pecuniary interest.
No other material transactions, earnings data or strategic changes are disclosed. The filing is purely an ownership disclosure under Rule 13d-1(c), signalling that Great Point now exceeds the 5 % threshold and is required to report its passive investment in Inventiva.